retatrutide clinical trial results weight loss retatrutide First phase 3 data, a Triumph of Science! retatrutide weight loss clinical trial

IRR 1.76

Using doses below the therapeutic threshold may provide insufficient metabolic benefit, essentially exposing patients to medication risks without meaningful clinical gain

Kunkle, A

Not only does it show how seamless and affordable medications can be when manufacturers come to the table and work around the common goal of patient affordability, it underscores how Express Scripts is constantly innovating to offer solutions that help the pharmacy benefit work as it should. The Patient Assurance program improves member affordability of select brand-name single-source drugs, increasing adherence and lowering downstream medical costs

The three rows are not three different weeks you run back to back they are snapshots of what a representative week looks like in each phase